High-dosage ascorbic acid treatment in charcot-marie-tooth disease type 1A results of a randomized, double-masked, controlled trial

JAMA Neurology

Volumn 70, Issue 8, 2013, Pages 981-987

  Lewis, Richard A ^a,f   McDermott, Michael P ^b,c   Herrmann, David N ^c   Hoke, Ahmet ^d   Clawson, Lora L ^d   Siskind, Carly ^a,g   Feely, Shawna M E ^a,h   Miller, Lindsey J ^a   Barohn, Richard J ^e   Smith, Patricia ^c   Luebbe, Elizabeth ^c   Wu, Xingyao ^a,h   Shy, Michael E ^a,h  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; MESSENGER RNA; PERIPHERAL MYELIN PROTEIN 22; PLACEBO;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CHARCOT MARIE TOOTH DISEASE TYPE 1A; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEARTBURN; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PMP22 GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING;

EID: 84882375832     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.3178     Document Type: Article

References (33)

1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet. 1974;6(2):98-118.
2. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66(2):219-232.
3. Raeymaekers P, Timmerman V, Nelis E, et al HMSN Collaborative Research Group. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). Neuromuscul Disord. 1991;1(2):93-97.
4. Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 1996;4(1):25-33.
5. Saporta ASD, Sottile SL,Miller LJ, Feely SME, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69(1):22-33.
6. Timmerman V, Nelis E, Van HulW, et al. The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication. Nat Genet. 1992;1(3):171-175.
7. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004;10(4):396-401.
8. Verhamme C, de Haan RJ, Vermeulen M, Baas F, de Visser M, van Schaik IN. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med. 2009;7: 70.
9. Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 2009;8(6): 537-544.
10. Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2009;8(12):1103-1110.
11. Pareyson D, Reilly MM, Schenone A, et al CMT-TRIAAL Group; CMT-TRAUK Group. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011;10(4): 320-328.
12. Reilly MM, de Jonghe P, Pareyson D. 136th ENMC InternationalWorkshop: Charcot-Marie- Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, the Netherlands. Neuromuscul Disord. 2006;16(6):396-402.
13. Weber P, Bendich A, SchalchW. Vitamin C and human health: a review of recent data relevant to human requirements. Int J Vitam Nutr Res. 1996;66(1):19-30.
14. Dyck PJ, LitchyWJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology. 1995;45(6):1115-1121.
15. Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005;64(7): 1209-1214.
16. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30(6):473-483.
17. Li J, Bai Y, Ghandour K, et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain. 2005;128(pt 5): 1168-1177.
18. Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology. 2007;68(11):849-855.
19. Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology. 2008;70(5):378-383.
20. Gordon PH, Cheung YK, Levin B, et al Combination Drug Selection Trial Study Group. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler. 2008;9(4):212-222.
21. Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington's disease. Mov Disord. 2010;25(13): 2219-2224.
22. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664-671.
23. Molenberghs G, Thijs H, Jansen I, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004;5(3):445-464.
24. Little RA, Rubin DB. Statistical AnalysisWith Missing Data. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2002.
25. Katona I,Wu X, Feely SM, et al. PMP22 expression in dermal nerve myelin from patients with CMT1A. Brain. 2009;132(pt 7):1734-1740.
26. Tesfaye S, Tandan R, Bastyr EJ III, Kles KA, Skljarevski V, Price KL; Ruboxistaurin Study Group. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care. 2007;30(10):2626-2632.
27. Dyck PJ, Norell JE, Tritschler H, et al. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care. 2007;30(10):2619-2625.
28. Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, de Visser M. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain. 2009;132(pt 12):3252-3262.
29. Thomas PK, MarquesWJr, Davis MB, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain. 1997;120(Pt 3):465-478.
30. Shy M, Lupski JR, Chance PF, Klein CJ, Dyck PJ. The hereditary motor and sensory neuropathies: an overview of the clinical, genetic, electrophysiologic and pathologic features. In: Dyck PJTP, ed. Peripheral Neuropathy. 4th ed. Philadelphia, PA:WB Saunders; 2005:1623-1658.
31. Burns J, Ouvrier R, Estilow T, et al. Validation of the Charcot-Marie-Tooth Disease Pediatric Scale as an outcome measure of disability. Ann Neurol. 2012;71(5):642-652.
32. Reilly MM, ShyME, Muntoni F, Pareyson D. 168th ENMC InternationalWorkshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord. 2010;20(12): 839-846.
33. Murphy SM, Herrmann DN, McDermott M.P., et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16(3):191-198.